New prostate cancer trial seeks to reduce toxicity without sacrificing efficacy
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.
“Our goal in this trial is to strategically improve both survival and quality of life for men living with advanced prostate cancer,” said Alliance study chair Thomas Hope, MD, a nuclear medicine physician and Professor in Residence at the University of California, San Francisco. “We hope to prove we can safely adjust the ...